BiotechTube

LP-184 + Spironolactone + Olaparib

Phase 1/2Recruiting
0 watching 0 views this week💤 Quiet
33
Hype Score

Development Stage

✓
Pre-clinical
2
Phase 1
3
Phase 2
4
Phase 3
5
Approved
Indication / Disease

Advanced Solid Tumor

Conditions

Advanced Solid Tumor, Metastatic Solid Tumor, GBM, TNBC - Triple-Negative Breast Cancer, NSCLC, Pancreatic Adenocarcinoma, DDR Gene Mutation

Trial Timeline

Jun 9, 2023 → Sep 9, 2025

NCT ID
NCT05933265

About LP-184 + Spironolactone + Olaparib

LP-184 + Spironolactone + Olaparib is a phase 1/2 stage product being developed by Lantern Pharma for Advanced Solid Tumor. The current trial status is recruiting. This product is registered under clinical trial identifier NCT05933265. Target conditions include Advanced Solid Tumor, Metastatic Solid Tumor, GBM.

Hype Score Breakdown

Clinical
13
Activity
8
Company
2
Novelty
4
Community
3

Clinical Trials (1)

NCT IDPhaseStatus
NCT05933265Phase 1/2Recruiting

Competing Products

20 competing products in Advanced Solid Tumor

See all competitors
ProductCompanyStageHype Score
AK-105AkesoPhase 1
32
AFM24 + Atezolizumab 840 MG in 14 ML InjectionAffimedPhase 1/2
33
EXS21546BiotrialPhase 1/2
33
SY-1365 (Part 1) + Carboplatin + Fulvestrant + SY-1365 (Cohort 2) + SY-1365 (Cohort 5) + SY-1365 (Part 2 Single Agent)Syros PharmaceuticalsPhase 1
25
Necitumumab + Gemcitabine + CarboplatinEli LillyPhase 2
52
Pemetrexed + Erlotinib + Pemetrexed + ErlotinibEli LillyPhase 2
52
NBTXR3NanobiotixPhase 1/2
36
pegfilgrastim + LY2523355Eli LillyPhase 1
33
SON-1010Sonnet BioTherapeuticsPhase 1
28
SON-1010Sonnet BioTherapeuticsPhase 1/2
36
BT1718Bicycle TherapeuticsPhase 1/2
33
Zentalis + GemzarZentalis PharmaceuticalsPhase 2
44
IMC-18F1Eli LillyPhase 1
33
Tadalafil + GemcitabineEli LillyPhase 1
33
OKI-179OnKure TherapeuticsPhase 1
25
OKI-219 + Fulvestrant + Trastuzumab + Tucatinib + Atirmociclib + RibociclibOnKure TherapeuticsPhase 1
25
LY3499446 + Abemaciclib + Cetuximab + Erlotinib + DocetaxelEli LillyPhase 1/2
41
LY3434172Eli LillyPhase 1
33
ACR-2316Acrivon TherapeuticsPhase 1
25
BBP-398LianBioPhase 1
25

Other Products from Lantern Pharma

Tavocept(BNP7787) in combination with cisplatin and either docetaxel or paclitaxel + Placebo in combination with cisplatin and docetaxel or paclitaxelPhase 3
69
BNP7787 + PlaceboPhase 3
69
IrofulvenPhase 2
44
LP-300 + Pemetrexed + CarboplatinPhase 2
44
STAR-001 (LP-184) will be administered via IV infusion over 30 (± 5) minutes on Day 1 and Day 8 of each 21-day cycle. + Spironolactone (drug)Phase 1/2
33